// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Glypican-6 is Identified as a Gene Responsible for Sporadic, Non-syndromic Tetralogy of Fallot Cases

Gennadiy Tenin - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Congenital disorder

Double outlet right ventricle

N/A

Association of Piezo1 Variants With Hypertension in UK Biobank Participants

Chew Cheng - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Essential arterial hypertension

N/A

Integrative Epidemiological and Functional Analyses Identify Protein C as a Novel, Causal Factor in Arterial and Venous Disease

Dirk S Paul - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Coronary Artery Disease

Protein C

A Systematic Review and Meta-Analysis of Transeptal vs Left Atrial Approach for Mitral Valve Surgery

Amer Harky - American Heart Association (AHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Robert L. Ferris - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples.

Marietta Scott - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

SP263

Retrospective study comparing survival when ipilimimab used with and without radiotherapy in patients with advanced melanoma.

Dominique Siobhan Parslow - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ipilimumab

Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.

Holger N. Lode - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

ch14.18

MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.

Martin Scurr - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cyclophosphamide

Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).

Manuel C. Maia - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Atezolizumab

Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.

David S. Hong - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dinoprostone

Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology.

Sergio Rutella - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma.

Rene Bruno - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Atezolizumab

Intratumoral administration of the alpha-Gal glycolipid AGI-134 to induce tumor regression in a mouse model of melanoma.

Stephen M. Shaw - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.

Yongwoo David Seo - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: The Blueprint-HCC study.

David James Pinato - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

SP263

Oral cavity squamous cell carcinoma and Waldeyer ring squamous cell carcinoma PDL-1 expression: A large, retrospective, single institution site series on head and neck squamous cell carcinoma, looking at the relationship with morphology, human papilloma virus and p16.

Chit Cheng Yeoh - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Two distinct clinical trajectories of inflammatory thyroiditis evoked by checkpoint blockade in malignant melanoma.

Anna Claire Olsson-Brown - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Changes in the use of commercial and lab-developed IVD assays in the clinical setting for PD-L1 expression testing in NSCLC in the United States.

Ayse Levent - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.

Dirk Schadendorf - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dabrafenib Mesylate

Copyright © 2026. QuantiNova All rights reserved